Atai Life Sciences N.V. focuses on operating as a holding company for ATAI Life Sciences AG that operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that are focused on multiple mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a GABA/nicotinic modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01 is a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.
IPO Year: 2008
Exchange: NASDAQ
Website: atai.life
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/20/2026 | $11.00 | Buy | Guggenheim |
| 10/13/2025 | $12.00 | Buy | Needham |
| 7/29/2025 | $14.00 | Outperform | Oppenheimer |
| 4/4/2025 | Buy | Berenberg | |
| 11/18/2024 | $15.00 → $10.00 | Buy | H.C. Wainwright |
| 4/3/2024 | $6.00 | Hold → Buy | Maxim Group |
| 11/1/2022 | $18.00 | Buy | Loop Capital |
| 11/30/2021 | $25.00 | Buy | Maxim Group |
| 11/22/2021 | $40.00 → $50.00 | Buy | HC Wainwright & Co. |
| 11/16/2021 | $25.00 → $24.00 | Outperform | Credit Suisse |
15-12G - Atai Beckley N.V. (0001840904) (Filer)
POSASR - Atai Beckley N.V. (0001840904) (Filer)
8-K - Atai Beckley N.V. (0001840904) (Filer)
424B7 - Atai Beckley N.V. (0001840904) (Filer)
10-Q - Atai Beckley N.V. (0001840904) (Filer)
8-K - Atai Beckley N.V. (0001840904) (Filer)
8-K - ATAI Life Sciences N.V. (0001840904) (Filer)
424B7 - ATAI Life Sciences N.V. (0001840904) (Filer)
8-K - ATAI Life Sciences N.V. (0001840904) (Filer)
8-K - ATAI Life Sciences N.V. (0001840904) (Filer)
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - ATAI Life Sciences N.V. (0001840904) (Issuer)
4 - ATAI Life Sciences N.V. (0001840904) (Issuer)
4 - ATAI Life Sciences N.V. (0001840904) (Issuer)
4 - ATAI Life Sciences N.V. (0001840904) (Issuer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Atai Beckley N.V. (0001840904) (Issuer)
4 - Atai Beckley N.V. (0001840904) (Issuer)
4 - Atai Beckley N.V. (0001840904) (Issuer)
4 - Atai Beckley N.V. (0001840904) (Issuer)
3 - Atai Beckley N.V. (0001840904) (Issuer)
3 - Atai Beckley N.V. (0001840904) (Issuer)
4 - ATAI Life Sciences N.V. (0001840904) (Issuer)
3 - ATAI Life Sciences N.V. (0001840904) (Issuer)
4 - ATAI Life Sciences N.V. (0001840904) (Issuer)
4 - ATAI Life Sciences N.V. (0001840904) (Issuer)
Fastest customizable press release news feed in the world
Issued on behalf of Helus PharmaVANCOUVER, BC, Feb. 27, 2026 /CNW/ -- Equity-Insider.com News Commentary -- Psychedelic compounds are edging closer to regulatory approval as pivotal trials in treatment-resistant depression and anxiety advance through late-stage development[1]. The sector is shedding its countercultural reputation as biotech firms reposition serotonergic and psychedelic-derived therapies as mainstream pharmaceutical candidates[2]. Five companies are building the clinical programs to get there: Helus Pharma (NASDAQ:HELP), AtaiBeckley (NASDAQ:ATAI), Definium Therapeutics (NASDAQ:DFTX), GH Research (NASDAQ:GHRS), and LB Pharmaceuticals (NASDAQ:LBRX).
EMP-01 met its primary objective on safety and tolerability, demonstrating a generally favorable and manageable safety and tolerability profileEMP-01 demonstrated a clinically meaningful placebo-adjusted least squares mean reduction of 11.85 points on the Liebowitz Social Anxiety Scale (LSAS) at Day 43 (Hedges' g = 0.45; p-value = 0.036, one-tailed)EMP-01 demonstrated a robust separation from placebo on the Clinician Global Impression–Improvement (CGI-I) assessment: 49% responders vs. 15% for placebo, corresponding to a Number Needed to Treat (NNT) of 2.95EMP-01 demonstrated improvements across both Fear and Avoidance sub-domains of the LSAS, including improvement in social avoidance behavio
NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ:ATAI) ("AtaiBeckley" or "Company"), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced that it will host a Virtual Investor Day on Friday, March 6, 2026, from 9:00 a.m. to 12:00 p.m. ET. The event will feature presentations and live Q&A sessions with members of the Company's executive leadership team and several external key opinion leaders. Investors, analysts, and members of the media are invited to register for the live webcast. A replay will be made available following the event on the investor
NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc (NASDAQ:ATAI) ("AtaiBeckley" or the "Company"), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced the appointment of Michael Faerm as Chief Financial Officer, effective March 9, 2026. Mr. Faerm is a seasoned financial executive with more than 25 years of experience across life sciences companies, equity research, and investment banking. As Chief Financial Officer at AtaiBeckley, he will lead the Company's financial strategy, capital markets activities, and overall financial operations. Anne Johnson, who ha
NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ:ATAI) ("AtaiBeckley" or "Company"), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced that Srinivas Rao, M.D., Ph.D., Co-Founder and Chief Executive Officer, and Jason Awe, Ph.D., Vice President of Investor Relations, will participate in fireside chats and host one-on-one meetings at the following investor conferences in March. TD Cowen 46th Annual Health Care Conference Format: Fireside chat, Wednesday, March 4, from 11:50am – 12:20pm EST and one-on-one meetingsLocation: Boston, Massachusetts Je
NEW YORK, Jan. 16, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ:ATAI) ("AtaiBeckley" or "Company"), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced its participation in the 64th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), which took place on January 12 - 15, 2026 in Nassau, The Bahamas. The Company presented new clinical and preclinical data supporting its development of transformative mental health therapies in two poster presentations and a Hot Topic Presentation. Dr. David Feifel, Professor Emeritus of Psychiatry at the Univer
NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc (NASDAQ:ATAI) ("AtaiBeckley" or the "Company"), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today provided its outlook for 2026 ahead of attendance at the J.P. Morgan 44th Annual Healthcare Conference in San Francisco, California, on January 12 – 15, 2026. Dr Srinivas Rao, Co-Founder and Chief Executive Officer of AtaiBeckley, said: "Following the strategic combination of atai Life Sciences and Beckley Psytech completed last year and the recent corporate redomiciliation to the United States, we enter 2026 with me
NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ:ATAI) ("AtaiBeckley" or "Company"), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today announced the completion of the redomiciliation of the parent company of the AtaiBeckley group from a Netherlands company to a U.S. entity incorporated in Delaware. The redomiciliation was approved by approximately 99% of the votes cast at the Company's extraordinary general meeting of shareholders on November 4, 2025. The redomiciliation was completed following the close of trading on the Nasdaq Global Market on Dece
NEW YORK and AMSTERDAM, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ:ATAI) ("AtaiBeckley" or "Company"), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today announced its common stock has been added to the NASDAQ Biotechnology Index (NASDAQ:NBI), effective prior to market open on Monday, December 22, 2025. "2025 has been a defining year for AtaiBeckley, marked by meaningful progress across our pipeline and corporate foundation. We strengthened our balance sheet by raising approximately $300 million, advanced multiple clinical programs toward late-stage deve
NEW YORK and AMSTERDAM, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ:ATAI) ("AtaiBeckley" or the "Company"), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today announced that the United States Patent and Trademark Office has granted a new patent covering EMP-01 (oral R-MDMA), further strengthening the company's intellectual property estate and long-term exclusivity for the program. The newly granted U.S. patent, No. 12,492,178, includes claims to the drug substance of EMP-01, and is expected to provide exclusivity through 2043. This patent identifies a hig
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Guggenheim initiated coverage of AtaiBeckley with a rating of Buy and set a new price target of $11.00
Needham initiated coverage of atai Life Sciences N.V. with a rating of Buy and set a new price target of $12.00
Oppenheimer initiated coverage of atai Life Sciences N.V. with a rating of Outperform and set a new price target of $14.00
Berenberg initiated coverage of atai Life Sciences N.V. with a rating of Buy
H.C. Wainwright reiterated coverage of atai Life Sciences N.V. with a rating of Buy and set a new price target of $10.00 from $15.00 previously
Maxim Group upgraded atai Life Sciences N.V. from Hold to Buy and set a new price target of $6.00
Loop Capital initiated coverage of atai Life Sciences N.V. with a rating of Buy and set a new price target of $18.00
Maxim Group initiated coverage of atai Life Sciences N.V. with a rating of Buy and set a new price target of $25.00
HC Wainwright & Co. reiterated coverage of ATAI Life Sciences with a rating of Buy and set a new price target of $50.00 from $40.00 previously
Credit Suisse reiterated coverage of ATAI Life Sciences with a rating of Outperform and set a new price target of $24.00 from $25.00 previously
Live Leadership Updates
NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc (NASDAQ:ATAI) ("AtaiBeckley" or the "Company"), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced the appointment of Michael Faerm as Chief Financial Officer, effective March 9, 2026. Mr. Faerm is a seasoned financial executive with more than 25 years of experience across life sciences companies, equity research, and investment banking. As Chief Financial Officer at AtaiBeckley, he will lead the Company's financial strategy, capital markets activities, and overall financial operations. Anne Johnson, who ha
- Srinivas Rao M.D., Ph.D. succeeds as sole Chief Executive Officer- Kevin Craig, M.D. promoted to Chief Medical Officer- Glenn Short, Ph.D. promoted to Chief Scientific Officer- Gerd Kochendoerfer, Ph.D. joins as Chief Operating Officer NEW YORK and BERLIN, Jan. 10, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced key leadership appointments to advance its goal of delivering novel mental health therapeutics. Srinivas Rao M.D., Ph.D., has assumed the role of sole Chief Executive Officer (CEO), joined by the promotions of Kevin Craig, M.D.
NEW YORK and BERLIN, May 23, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the appointment of Scott Braunstein, M.D., and Laurent Fischer, M.D., as independent directors of atai's supervisory board ("Board") subject to applicable legal requirements. Scott Braunstein, M.D., is the Chief Executive Officer ("CEO") and Chairman of Marinus Pharmaceuticals, Inc. He is an operating partner at Aisling Capital and serves on the Board of Directors at both Caribou Biosciences, Inc. and Trevena Inc. Previously, Dr. Braunstein was Chief Operati
NEW YORK and BERLIN, Feb. 06, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company") today announced that Anne Johnson, the Company's interim Chief Financial Officer since October 2023 and Chief Accounting Officer since August 2022, has been named Chief Financial Officer (CFO). Anne succeeds Stephen Bardin as the Company's CFO while Stephen will continue in an advisory role until March 31, 2024 to support the transition. "Anne has been an integral member of our team for over three years and has demonstrated the executive leadership, financial acumen, and track record to lead our financial organization with excellence," said atai Co-founder and Chief Executive Off
Cognito Therapeutics, a pioneer developing disease-modifying therapeutics to treat CNS diseases, today announced the appointment of Greg Weaver as Chief Financial Officer (CFO), to lead all finance-related and investor relations functions at the Company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231017630946/en/Greg Weaver, CFO, Cognito Therapeutics (Photo: Business Wire) Mr. Weaver is a highly accomplished finance executive who brings more than 30 years of life sciences, financial and operations experience to Cognito. Most recently, he served as CFO of Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage oncology comp
SEATTLE, June 01, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a current focus on breast cancer, today announces the appointment of Greg Weaver as the Company's new Chief Financial Officer (CFO). Mr. Weaver succeeds Kyle Guse. A short video interview with Mr. Weaver about his background and vision for Atossa can be found here: https://youtu.be/G6ZzHLh-qsQ Mr. Weaver brings more than 30 years of life sciences, financial and operations experience to the Company. Recently, he served as CFO of privately held BioIntelliSense, a commerc
- Dr. Kirpekar joins from Otsuka Pharmaceutical where he was Head of Business Development and Co-chair of the Global Business Development Committee - - He has spent more than 15 years building and growing organizations and businesses in the life sciences and digital health industries - - His deal sheet includes transactions totaling more than USD 2.7 billion in CNS and beyond - NEW YORK and BERLIN, Nov. 29, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V., (NASDAQ:ATAI) ("atai" or the "Company"), a clinical stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced today its appointment of Dr. Kirpekar to serve as the Company's Chief Busines
FN Media Group Presents Microsmallcap.com Market Commentary NEW YORK, Aug. 10, 2022 /PRNewswire/ -- Toronto's Center for Addiction and Mental Health (CAMH) just received the first-ever federal grant to study whether the active component of "magic" mushrooms can be used to treat depression. Researchers will explore whether the psychoactive effects are necessary to relieve treatment-resistant depression in adults. According to CAMH's lead investigator, clinical trials suggest that psilocybin, combined with psychotherapy, can produce "sustained antidepressant effects" in individuals living with severe depression. This news comes just days after a major scientific review found "no clear evidence
NEW YORK, June 30, 2022 (GLOBE NEWSWIRE) -- Kures Therapeutics, Inc ("Kures"), an atai Life Sciences N.V. (NASDAQ:ATAI) ("atai") company focused on developing treatment options to better manage addictions, depression, and pain, today announced the appointment of Chad E. Beyer, Ph.D., MBA, currently Senior Vice President of Research and Development at Promentis Pharmaceuticals, Inc ("Promentis"), as Chief Executive Officer of Kures, effective July 1, 2022. Dr. Beyer has over 25 years of experience in the discovery, research and translational development of medications that treat the central nervous system and neurological disorders. He has led several preclinical and clinical drug discove
Live finance-specific insights
EMP-01 met its primary objective on safety and tolerability, demonstrating a generally favorable and manageable safety and tolerability profileEMP-01 demonstrated a clinically meaningful placebo-adjusted least squares mean reduction of 11.85 points on the Liebowitz Social Anxiety Scale (LSAS) at Day 43 (Hedges' g = 0.45; p-value = 0.036, one-tailed)EMP-01 demonstrated a robust separation from placebo on the Clinician Global Impression–Improvement (CGI-I) assessment: 49% responders vs. 15% for placebo, corresponding to a Number Needed to Treat (NNT) of 2.95EMP-01 demonstrated improvements across both Fear and Avoidance sub-domains of the LSAS, including improvement in social avoidance behavio
A 12 mg dose of BPL-003 (mebufotenin benzoate nasal spray) administered eight weeks after an initial 12 mg, 8 mg or 0.3 mg dose in the core study of the Phase 2b clinical trial produced additional rapid, clinically meaningful antidepressant effects that were sustained for up to eight weeksPatients who received an active dose of BPL-003 in the core study of the Phase 2b clinical trial (either 8 mg or 12 mg) met response and remission criteria for depression at increased rates after receiving a 12 mg dose in the OLE study, with 63% in response and 48% in remission at Week 8 in the OLE study (Week 16 of the Phase 2b clinical trial)An End-of-Phase 2 meeting has been scheduled with the U.S. Food
Study met its primary and all key secondary endpoints, and BPL-003 demonstrated rapid, robust and durable antidepressant effects with a single doseBoth 8 mg and 12 mg single doses of BPL-003 showed statistically significant and clinically meaningful reductions in depressive symptoms at all time points of the study compared to a 0.3 mg low-dose active control out to Week 8BPL-003 was generally well-tolerated at all doses, with 99% of treatment-emergent adverse events being mild or moderate, and no drug-related serious adverse events or suicide-related safety signalsMajority of patients deemed ready for discharge at the 90 minutes post-dose assessment, which suggests BPL-003 could fit within t
Strategic combination establishes a market-leading mental health company with a pipeline that includes potentially transformative, rapid-acting psychedelic assets differentiated by their convenient route of administration and short time-in-clinicCombined company will operate under the name atai Beckley with a joint leadership team and Board that leverage the deep psychedelic, drug development and CNS expertise within both organizationsTopline data from the Phase 2b study of BPL-003 in patients with treatment-resistant depression (TRD) is expected in mid-2025 - the largest controlled trial of mebufotenin (5-MeO-DMT) and the first and only controlled trial to investigate mebufotenin in the U.S
Strategic investment in Beckley Psytech reinforces atai's position as the biopharmaceutical company with the largest and most diverse portfolio of clinical-stage psychedelic candidatesTwo patent-protected, clinical-stage programs BPL-003 (intranasal 5-MeO-DMT) and ELE-101 (intravenous psilocin) complement atai's existing drug development programs Multiple clinical readouts anticipated from this investment in Beckley Psytech within next 12 months, including a Phase 2b readout of BPL-003 in Treatment Resistant Depression in 2H24 BPL-003 has the potential to become a first-in-class short-duration psychedelic treatment with rapid acting and durable antidepressant effects Anticipated synergies th
– Highlights included positive Phase 2b data with COMP360 from a ground-breaking treatment resistant depression (TRD) trial, highly encouraging Phase 2a proof-of-mechanism data with RL-007 in cognitive impairment associated with schizophrenia (CIAS), clinical trial initiations with PCN-101, GRX-917 and DMX-1002, and successful completion of 2 cohorts in the Introspect Digital Therapeutics ketamine trials – Eight new programs added to platform since January 2021 bringing total, as of today, to 13 discovery and drug development programs and four enabling technologies – Ended 2021 very well capitalized with $362 million to execute our strategy to achieve clinically meaningful and sustai
NEW YORK and BERLIN, March 23, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (NASDAQ:ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it plans to host a webcast on Wednesday, March 30, 2022 at 8:30 a.m. ET to discuss its financial results for the fourth quarter 2021 and provide a business update. To access the webcast, please log in at https://wsw.com/webcast/cc/atai/1358298. The live and archived webcast of this call will be available in the "Events" section of the atai Life Sciences website at ir.atai.life. About atai Life Sciences atai was founded in 2018 as a response to the significant
-Positive topline results from COMP360's Phase 2b study- -RL-007 Phase 2a topline data in cognitive impairment associated with schizophrenia expected end of Q4- -Continued progress across 11 therapeutic programs, including initiation of Perception's Phase 2a and DemeRx's Phase 1/2 trials as well as interim Phase 2a RL-007 readout of first cohort- -Launch of atai Impact, a philanthropic program to harness the power of innovative mental health approaches for social change- -Company to host a webcast and conference call today at 08:30am EST- BERLIN and NEW YORK, Nov. 15, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (NASDAQ:ATAI) ("atai"), a clinical-stage biopharmaceutical company ai
NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (NASDAQ:ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it plans to host a conference call on Monday, November 15, 2021 at 8:30 a.m. ET to discuss its financial results for the quarter ended September 30, 2021 and provide a business update. To access the live conference call, please dial 877-407-3982 from the United States, or +1 (201) 493-6780 internationally, using the conference ID: 13724750. The live and archived webcast of this call will be available in the "Events" section of the atai Life Sciences website at ir.atai.life.
BERLIN, Aug. 09, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (NASDAQ:ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it plans to host a conference call on Monday, August 16, 2021 at 8:30 a.m. ET to discuss its financial results for the quarter ended June 30, 2021 and provide a business update. To access the live conference call, please dial 877-407-3982 from the United States, or +1 (201) 493-6780 internationally, using the conference ID: 13721888. The live and archived webcast of this call will be available in the "Events" section of the atai Life Sciences website at ir.atai.life. Abou
This live feed shows all institutional transactions in real time.
SC 13D/A - ATAI Life Sciences N.V. (0001840904) (Filed by)
SC 13D/A - ATAI Life Sciences N.V. (0001840904) (Filed by)
SC 13D/A - ATAI Life Sciences N.V. (0001840904) (Filed by)
SC 13G/A - ATAI Life Sciences N.V. (0001840904) (Subject)
SC 13D/A - ATAI Life Sciences N.V. (0001840904) (Filed by)
SC 13G/A - ATAI Life Sciences N.V. (0001840904) (Subject)
SC 13G - ATAI Life Sciences N.V. (0001840904) (Subject)
SC 13G - ATAI Life Sciences N.V. (0001840904) (Subject)
SC 13D/A - ATAI Life Sciences N.V. (0001840904) (Filed by)
SC 13D/A - ATAI Life Sciences N.V. (0001840904) (Filed by)